Under 10% of individuals eligible to benefit from GLP-1 drugs including Wegovy are able to get them, warns the WHO as it releases its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key obstacles to universal access to the jabs that can aid individuals in losing substantial weight, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, according to the health organization.
The advice encourages nations and manufacturers to widen availability, by strategies including patent sharing.
A patent on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Drugs Function
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so individuals reduce food intake.
Individuals commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies indicates users may put most of the weight back on after a year of halting the drug, when their normal food cravings return.
Being overweight or obese increases your risk for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
